Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cognitive Deficits in Schizophrenia Clear all
Recruiting Phase 2 Interventional

Study of ALTO-101 in Patients With Schizophrenia

NCT06502964
View directory record Official record
Conditions
Schizophrenia, Cognitive Impairment
Interventions
ALTO-101, ALTO-101 Transdermal Delivery System, Placebo, Placebo Transdermal Delivery System
Drug · Device
Lead sponsor
Alto Neuroscience
Industry
Eligibility
21 Years to 55 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
14
States / cities
Garden Grove, California • Los Angeles, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Not applicable Interventional

Treating Thought Problems in Patients With Schizophrenia

NCT00051740
View directory record Official record
Conditions
Schizophrenia
Interventions
Cognitive Adaptation Therapy (CAT), Minimal Environmental Supports (MES)
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Phase 2 Interventional

Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults

NCT01266174
View directory record Official record
Conditions
Cognitive Impairment, Schizophrenia
Interventions
Eltoprazine, Placebo
Drug
Lead sponsor
Amarantus BioScience Holdings, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Los Angeles, California • Chicago, Illinois • Catonsville, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Phase 2 Interventional

Evaluation of a Cognitive Adaptive E-treatment in Schizophrenia-diagnosed Adults

NCT01422902
View directory record Official record
Conditions
Schizophrenia
Interventions
Plasticity-based Cognitive Training, Non-plasticity-based Training
Other
Lead sponsor
Posit Science Corporation
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Palo Alto, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Not applicable Interventional

Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia

NCT00161031
View directory record Official record
Conditions
Schizophrenia
Interventions
Atomoxetine
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Baltimore, Maryland • Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2019 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Alcohol Dependence and Comorbid Bipolar Disorder

NCT01015586
View directory record Official record
Conditions
Alcohol Dependence, Bipolar Disorder, Depression, Mania, Psychosis
Interventions
Lamotrigine, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Jul 23, 2026, 10:48 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype

NCT00548327
View directory record Official record
Conditions
Schizophrenia, Memory Disorders, Cognition Disorders
Interventions
Atomoxetine, Functional magnetic resonance imaging, Neuropsychological Testing, Placebo
Drug · Procedure
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 45 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 13, 2013 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset Schizophrenia

NCT01773239
View directory record Official record
Conditions
Schizophrenia
Interventions
TARA computer-based exercises
Behavioral
Lead sponsor
Posit Science Corporation
Industry
Eligibility
18 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

CRT-Guanfacine for SPD

NCT02524899
View directory record Official record
Conditions
Schizotypal Personality Disorder, SPD
Interventions
Cognitive Remediation Therapy, Guanfacine, Placebo
Behavioral · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Jul 23, 2026, 10:48 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia

NCT00439634
View directory record Official record
Conditions
Schizophrenia
Interventions
AVE1625, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
873 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers

NCT01749098
View directory record Official record
Conditions
Schizophrenia
Interventions
PF-04958242, Ketamine, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
21 Years to 45 Years · Male only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
New Haven, Connecticut • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Peer Support for Increasing Physical Activity in People With Serious Mental Illnesses

NCT00458094
View directory record Official record
Conditions
Schizophrenia, Depression, Bipolar Disorder, Anxiety Disorders, Cognitive Disorders, Personality Disorders
Interventions
Physical activity intervention with peer support (PA+PS), Physical activity intervention without peer support (PA)
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Phase 2 Interventional

Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia

NCT01488929
View directory record Official record
Conditions
Schizophrenia, Negative Symptoms, Cognitive Dysfunction
Interventions
TC-5619, Placebo
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
22
States / cities
Garden Grove, California • Glendale, California • Long Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Phase 4 Interventional Results available

Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors

NCT00802919
View directory record Official record
Conditions
Schizophrenia, Cigarette Smoking
Interventions
Varenicline, Placebo for varenicline
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 65 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
New York, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers

NCT01959594
View directory record Official record
Conditions
Healthy
Interventions
3 mg PF-06412562, 10 mg PF-06412562, 25 mg PF-06412562, PF-06412562 TBD mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced Jul 23, 2026, 10:48 PM EDT
Withdrawn Phase 4 Interventional

Once Weekly D-cycloserine for Schizophrenia

NCT00964041
View directory record Official record
Conditions
Schizophrenia
Interventions
D-cycloserine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Armodafinil as Adjunctive Therapy in Schizophrenic Adults With Cognitive Deficits

NCT00487942
View directory record Official record
Conditions
Schizophrenia
Interventions
armodafinil, placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
12
States / cities
Garden Grove, California • National City, California • Paramount, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Phase 4 Interventional Results available

Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia

NCT00176423
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
galantamine
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2020 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Phase 1 Interventional

Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia

NCT01394471
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Intranasal Oxytocin Spray
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Jul 23, 2026, 10:48 PM EDT
Recruiting Not applicable Interventional

Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis Risk

NCT05131035
View directory record Official record
Conditions
Psychosis, Prodromal Schizophrenia, Prodromal Symptoms
Interventions
SCORES (Specific COgnitive Remediation with Support)
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
14 Years to 20 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Phase 3 Interventional

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

NCT01716975
View directory record Official record
Conditions
Schizophrenia, Impaired Cognition
Interventions
EVP-6124, Placebo
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
767 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
49
States / cities
Phoenixville, Arizona • Little Rock, Arkansas • Cerritos, California + 46 more
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Jul 23, 2026, 10:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Velocardiofacial (VCFS; 22q11.2; DiGeorge) Syndrome Study

NCT00105274
View directory record Official record
Conditions
DiGeorge Syndrome, Velocardiofacial Syndrome, 22q11.2 Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KYN-5356 in Healthy Subjects Aged 18 to 55 Years

NCT06225115
View directory record Official record
Conditions
Cognitive Dysfunction, Schizophrenia
Interventions
KYN-5356, placebo
Drug
Lead sponsor
Kynexis B.V.
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Jul 23, 2026, 10:48 PM EDT
Completed Phase 1 Interventional

N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia

NCT01885338
View directory record Official record
Conditions
Schizophrenia
Interventions
N-acetylcysteine (NAC), Inactive placebo capsule
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Jul 23, 2026, 10:48 PM EDT